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Abstract 
Recently, zonisamide (ZNS) has been approved as a new adjunctive therapy for motor 
complications of Parkinson’s disease (PD). More recently, ZNS was reported to be effective 
for the management of impulse control behavior in PD, suggesting potential effects on non-
motor PD symptoms. Dream enactment associated with aggressive, violent behavior can 
carry a serious risk of injury to patients, as well as to spouses or caretakers. This report 
describes a patient with PD who had vivid nightmares and dream-enacting behavior that 
resolved after treatment with ZNS. The present case raises the question whether ZNS might 
potentially be effective for the management of vivid nightmares or dream-enacting 
behavior. 
 
Introduction 
Zonisamide (ZNS) is an antiepileptic drug that has recently been approved in many 
countries. It is also effective for the management of migraine [1], neuropathic pain [2], 
essential tremor [3], anxiety [4], and other conditions. Recently, ZNS has been approved 
as a new adjunctive therapy for motor complications of Parkinson’s disease (PD) in 
Japan [5]. More recently, ZNS was reported to be effective for the management of 
impulse control behavior in PD [6], suggesting potential effects on non-motor PD 
symptoms. Dream enactment associated with aggressive, violent behavior can carry a 
serious risk of injury to patients, as well as to spouses or caretakers. We describe a 
patient with PD who had vivid nightmares and dream-enacting behavior that resolved 
after treatment with ZNS.  
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Case Report 
In 2009, a 71-year-old man with a history of pulmonary surgery noticed tremor of the left hand 
and akinesia. In March 2010, he showed features of moderate parkinsonism, including masked face, 
stooped posture, bradykinesia, left-side-dominant rigidity, and resting tremor. Cranial nerve, sensory, 
and cerebellar functions were intact. The results of cranial magnetic resonance imaging were normal. 
Bradykinesia, rigidity, and resting tremor responded to treatment with pramipexole (0.5 mg/day). 
Since July 2010, his wife was awakened nearly every night because of the patient’s aggressive or 
violent behavior during the middle of the night. For example, he suddenly flew up or walked, collided 
with furniture or walls, cried out, or exercised his limbs noisily. He was often injured. On the nights he 
presented with this behavior, he remembered having vivid nightmares, such as being chased by a cat, 
bear, or his wife or of fighting with a thief or grandchild. These nightmares were documented in 
personal interviews. Interviews with the patient’s wife indicated that this aggressive, violent behavior 
during the night occurred sometimes in 2009. In April 2011, stooped posture and lumbar pain 
developed, which were attributed to pramipexole. We switched from pramipexole (1.0 mg/day, once 
before sleep) to ZNS (25 mg/day, once before sleep). Before switching to ZNS, motor and non-motor 
symptoms were as follows: the scores on parts I, II, III, and IV of the unified Parkinson’s disease rating 
scale (UPDRS) were 3, 5, 17, and 0, respectively. The scores on the Mini-Mental State Examination 
(29/30) and Frontal Assessment Battery (18/18) were normal. The heart-mediastinum 123I-
metaiodobenzylguanidine uptake ratio was significantly decreased. Because he noticed reduced 
olfactory sensitivity, we assessed olfactory recognition ability by using the Odor Stick Identification 
Test for Japanese (OSIT-J), as described previously [7]. Briefly, the OSIT-J tests for 13 kinds of odors 
familiar to Japanese people (curry, cooking gas, perfume, Japanese cypress, India ink, menthol, nattou 
[fermented soybeans]/sweaty socks, rose, putrid smell, wood, roasted garlic, condensed milk, 
Japanese orange). We asked the patient to choose an answer among four possible odor names, one of 
which was correct, plus ‘detectable but not recognizable’ and ‘odorless’. He could identify four odors 
(perfume, curry, cooking gas, and condensed milk). The identification rate was 33%, consistent with 
that of patients with olfactory disturbances (36 ± 34%). The score on the Pittsburgh sleep quality 
index (ranging from 14 for normal to 56 for unsleeping) was 16, and the 2-point increase above 
normal was ascribed to difficulty in sleeping caused by nightmares. He fell asleep in 5 minutes and 
slept for 7 h without sleep fragmentation. He did not experience hallucinations or pleasant dreams 
during follow-up. In May, he could never remember his dreams, and the nightmares disappeared. His 
wife was no longer awakened since the patient’s aggressive and violent behavior had resolved. Motor 
features, including the UPDRS score, were unchanged. This state has persisted for 7 months. In 
November 2011, we obtained informed consent from the patient and tested whether pramipexole 
elicited nightmares or violent behavior. First, he was given pramipexole (0.5 mg/day) in the context 
of stable doses of ZNS (25 mg/day) for 2 weeks. Subsequently, ZNS was withdrawn, and pramipexole 
was continued for 2 weeks. No nightmares or violent behavior appeared. 
Discussion 
Our patient showed aggressive and violent behavior associated with vivid 
nightmares, which probably preceded such behavior, during the middle of the night. He 
did not have a history of hallucinations. This disorder strongly suggested a rapid-eye-
movement sleep behavior disorder (RBD). In our patient, who had RBD while receiving 
pramipexole, RBD was completely resolved by switching from pramipexole to ZNS. 
Dopamine agonists can lead to vivid dreams, nightmares, and parasomnia-like motor 
activity [8], but RBD in our patient was not induced by rechallenge with pramipexole. 
In patients with PD, pramipexole was reported to be effective for RBD [9], but to 
worsen REM sleep electromyographic abnormalities on video-polysomnography [10]. 
One study showed that pramipexole did not improve RBD in PD, and the authors 
mentioned that RBD in PD may be either 2 different stages of the same condition or 2 
completely different conditions [11]. This can explain our observations during 
treatment with pramipexole, but we believe that pramipexole did not alter RBD in our 
patient since the wife’s interviews indicated that RBD was evident before starting  
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pramipexole. This notion is supported by the results of a previous study [11] showing 
that the frequency and severity of RBD were unaffected by pramipexole therapy. RBD 
itself can disappear in the natural history of PD [12]. However, our finding raises an 
open question whether ZNS is useful for treating RBD in patients with early PD. 
Abnormal dreams in RBD contribute to the control of enacted behavior [13]. Dream 
generators are suppressed by inhibition of brainstem locomotor pattern generators, 
which can modify dream content in RBD [13]. Dopaminergic dysfunction may play a 
role in the pathophysiology of RBD [14] and dopamine modulates the expression of 
locomotion and other rhythmic motor patterns in neural circuits known as central 
pattern generators [15]. A ZNS-induced effect on the dopaminergic system might have 
modulated or inhibited brainstem locomotor pattern generators, consequently 
suppressing vivid nightmares, leading to the resolution of dream-enacting behavior. 
Our experience suggests that ZNS potentially might be effective for the management of 
vivid nightmares or dream-enacting behavior in patients with early PD. 
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